4//SEC Filing
Tardio Jason 4
Accession 0001209191-22-024191
CIK 0001636651other
Filed
Apr 11, 8:00 PM ET
Accepted
Apr 12, 5:40 PM ET
Size
8.0 KB
Accession
0001209191-22-024191
Insider Transaction Report
Form 4
Tardio Jason
Chief Commercial Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-04-08+87,498→ 87,498 totalExercise: $3.22Exp: 2023-04-07→ Common Stock (87,498 underlying) - Award
Stock Option (Right to Buy)
2022-04-08+10,000→ 10,000 totalExercise: $3.22Exp: 2023-04-07→ Common Stock (10,000 underlying)
Footnotes (2)
- [F1]The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable October 8, 2022 and the remaining shares will vest in 18 equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
- [F2]The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable on April 8, 2023 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous services through such vesting date.
Documents
Issuer
Ovid Therapeutics Inc.
CIK 0001636651
Entity typeother
Related Parties
1- filerCIK 0001794698
Filing Metadata
- Form type
- 4
- Filed
- Apr 11, 8:00 PM ET
- Accepted
- Apr 12, 5:40 PM ET
- Size
- 8.0 KB